Silexion Therapeutics Corp Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Silexion Therapeutics Corp has an operating margin of -44896.4%, meaning the company retains $-44896 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -3059.5% the prior year.
Silexion Therapeutics Corp's revenue declined 81.7% year-over-year, from $153K to $28K. This contraction results in a growth score of 0/100.
Silexion Therapeutics Corp's current ratio of 0.64 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 6/100, which could limit financial flexibility.
While Silexion Therapeutics Corp generated -$8.4M in operating cash flow, capex of $22K consumed most of it, leaving -$8.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Silexion Therapeutics Corp passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, Silexion Therapeutics Corp generates $0.51 in operating cash flow (-$8.4M OCF vs -$16.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Silexion Therapeutics Corp earns $-465.6 in operating income for every $1 of interest expense (-$12.6M vs $27K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Silexion Therapeutics Corp (SLXN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 2 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Silexion Therapeutics Corp generated $28K in revenue in fiscal year 2024. This represents a decrease of 81.7% from the prior year.
Silexion Therapeutics Corp's EBITDA was -$12.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 170.6% from the prior year.
Silexion Therapeutics Corp generated -$8.4M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 85.4% from the prior year.
Silexion Therapeutics Corp reported -$16.5M in net income in fiscal year 2024. This represents a decrease of 223.4% from the prior year.
Silexion Therapeutics Corp earned $394.94 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 40.1% from the prior year.
Silexion Therapeutics Corp held $1.2M in cash against $0 in long-term debt as of fiscal year 2024.
Silexion Therapeutics Corp had 8.41B shares outstanding in fiscal year 2024. This represents an increase of 129137637.9% from the prior year.
Silexion Therapeutics Corp's operating margin was -44896.4% in fiscal year 2024, reflecting core business profitability. This is down 41836.9 percentage points from the prior year.
Silexion Therapeutics Corp's net profit margin was -58996.4% in fiscal year 2024, showing the share of revenue converted to profit. This is down 55657.9 percentage points from the prior year.
Silexion Therapeutics Corp invested $5.8M in research and development in fiscal year 2024. This represents an increase of 56.8% from the prior year.
Silexion Therapeutics Corp invested $22K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 83.3% from the prior year.
SLXN Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $39K-11.4% | $44K+2100.0% | $2K-33.3% | $3K-50.0% | $6K-68.4% | $19K | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.2M+111.9% | $1.0M+72.5% | $590K-32.3% | $871K+13.7% | $766K-20.3% | $961K | N/A | $535K |
| SG&A Expenses | $1.1M-10.3% | $1.3M+19.4% | $1.1M+3.0% | $1.0M+66.2% | $619K+114.2% | $289K | N/A | $196K |
| Operating Income | -$3.3M-44.1% | -$2.3M-38.4% | -$1.6M+13.2% | -$1.9M-37.2% | -$1.4M-10.8% | -$1.3M | N/A | -$731K |
| Interest Expense | $0 | $0-100.0% | $11K+140.7% | -$27K | $0 | $0 | N/A | N/A |
| Income Tax | $0-100.0% | $3K | N/A | $1K-50.0% | $2K-60.0% | $5K | N/A | $6K |
| Net Income | -$3.3M-30.3% | -$2.5M-44.3% | -$1.7M+0.7% | -$1.7M-17.3% | -$1.5M-4.6% | -$1.4M | N/A | -$809K |
| EPS (Diluted) | $2.88 | $4.32+1561.5% | $0.26 | $-89.40 | $197.80+1509.4% | $12.29 | N/A | $0.78 |
SLXN Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.6M+100.3% | $5.8M-30.2% | $8.3M+190.2% | $2.9M+23.7% | $2.3M-35.4% | $3.6M-31.8% | $5.3M | N/A |
| Current Assets | $11.1M+111.1% | $5.2M-32.2% | $7.7M+243.2% | $2.3M-2.8% | $2.3M | N/A | $5.0M | N/A |
| Cash & Equivalents | $9.2M+166.7% | $3.5M-43.7% | $6.2M+418.3% | $1.2M-30.1% | $1.7M-40.1% | $2.8M-38.4% | $4.6M-20.9% | $5.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $4.6M-18.3% | $5.7M-0.8% | $5.7M-16.5% | $6.9M-66.7% | $20.6M+941.6% | $2.0M-90.5% | $20.7M | N/A |
| Current Liabilities | $2.8M+29.6% | $2.1M-10.2% | $2.4M-32.0% | $3.5M+49.0% | $2.4M | N/A | $2.2M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $7.0M+5714.2% | $120K-95.4% | $2.6M+164.8% | -$4.0M+78.2% | -$18.3M-1234.0% | $1.6M+110.4% | -$15.5M-233.0% | -$4.6M |
| Retained Earnings | -$50.8M-6.9% | -$47.5M-5.6% | -$45.0M-4.0% | -$43.3M-45.9% | -$29.7M | N/A | -$26.8M | N/A |
SLXN Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.8M-13.4% | -$2.5M-2.2% | -$2.5M+16.2% | -$2.9M-174.7% | -$1.1M+39.2% | -$1.8M-39.4% | -$1.3M-83.5% | -$685K |
| Capital Expenditures | $0-100.0% | $1K-83.3% | $6K | $0 | $0-100.0% | $6K+50.0% | $4K-33.3% | $6K |
| Free Cash Flow | -$2.8M-13.4% | -$2.5M-2.0% | -$2.5M+16.0% | -$2.9M-174.7% | -$1.1M+39.4% | -$1.8M-39.4% | -$1.3M-82.5% | -$691K |
| Investing Cash Flow | $0+100.0% | -$1K+83.3% | -$6K | $0 | $0+100.0% | -$6K-50.0% | -$4K-105.6% | $72K |
| Financing Cash Flow | $8.6M+4522.6% | -$195K-102.6% | $7.4M+240.3% | $2.2M | $0 | N/A | $0 | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
SLXN Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -8441.0%-3250.1pp | -5190.9%+77309.1pp | -82500.0%-19166.7pp | -63333.3%-40250.0pp | -23083.3%-16504.4pp | -6579.0% | N/A | N/A |
| Net Margin | -8364.1%-2675.5pp | -5688.6%+81061.4pp | -86750.0%-28516.7pp | -58233.3%-33416.7pp | -24816.7%-17327.2pp | -7489.5% | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -28.1%+15.1pp | -43.2%-22.3pp | -20.9%+40.1pp | -61.0%+3.3pp | -64.3%-24.6pp | -39.7% | N/A | N/A |
| Current Ratio | 3.97+1.5 | 2.44-0.8 | 3.22+2.6 | 0.64-0.3 | 0.98 | N/A | 2.27 | N/A |
| Debt-to-Equity | 0.66-46.6 | 47.31+45.1 | 2.21+3.9 | -1.72-0.6 | -1.13-2.4 | 1.23+2.6 | -1.34 | N/A |
| FCF Margin | -7289.7%-1589.7pp | -5700.0%+117250.0pp | -122950.0%-25416.7pp | -97533.3%-79783.3pp | -17750.0%-8497.4pp | -9252.6% | N/A | N/A |
Note: Shareholder equity is negative (-$4.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.64), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is Silexion Therapeutics Corp's annual revenue?
Silexion Therapeutics Corp (SLXN) reported $28K in total revenue for fiscal year 2024. This represents a -81.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Silexion Therapeutics Corp's revenue growing?
Silexion Therapeutics Corp (SLXN) revenue declined by 81.7% year-over-year, from $153K to $28K in fiscal year 2024.
Is Silexion Therapeutics Corp profitable?
No, Silexion Therapeutics Corp (SLXN) reported a net income of -$16.5M in fiscal year 2024, with a net profit margin of -58996.4%.
What is Silexion Therapeutics Corp's earnings per share (EPS)?
Silexion Therapeutics Corp (SLXN) reported diluted earnings per share of $394.94 for fiscal year 2024. This represents a -40.1% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Silexion Therapeutics Corp's EBITDA?
Silexion Therapeutics Corp (SLXN) had EBITDA of -$12.5M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Silexion Therapeutics Corp's operating margin?
Silexion Therapeutics Corp (SLXN) had an operating margin of -44896.4% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Silexion Therapeutics Corp's net profit margin?
Silexion Therapeutics Corp (SLXN) had a net profit margin of -58996.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Silexion Therapeutics Corp's free cash flow?
Silexion Therapeutics Corp (SLXN) generated -$8.4M in free cash flow during fiscal year 2024. This represents a -85.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Silexion Therapeutics Corp's operating cash flow?
Silexion Therapeutics Corp (SLXN) generated -$8.4M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Silexion Therapeutics Corp's total assets?
Silexion Therapeutics Corp (SLXN) had $2.9M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Silexion Therapeutics Corp's capital expenditures?
Silexion Therapeutics Corp (SLXN) invested $22K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Silexion Therapeutics Corp spend on research and development?
Silexion Therapeutics Corp (SLXN) invested $5.8M in research and development during fiscal year 2024.
How many shares does Silexion Therapeutics Corp have outstanding?
Silexion Therapeutics Corp (SLXN) had 8.41B shares outstanding as of fiscal year 2024.
What is Silexion Therapeutics Corp's current ratio?
Silexion Therapeutics Corp (SLXN) had a current ratio of 0.64 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
What is Silexion Therapeutics Corp's debt-to-equity ratio?
Silexion Therapeutics Corp (SLXN) had a debt-to-equity ratio of -1.72 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Silexion Therapeutics Corp's return on assets (ROA)?
Silexion Therapeutics Corp (SLXN) had a return on assets of -577.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Silexion Therapeutics Corp's cash runway?
Based on fiscal year 2024 data, Silexion Therapeutics Corp (SLXN) had $1.2M in cash against an annual operating cash burn of $8.4M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Silexion Therapeutics Corp's debt-to-equity ratio negative or unusual?
Silexion Therapeutics Corp (SLXN) has negative shareholder equity of -$4.0M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Silexion Therapeutics Corp's Piotroski F-Score?
Silexion Therapeutics Corp (SLXN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Silexion Therapeutics Corp's earnings high quality?
Silexion Therapeutics Corp (SLXN) has an earnings quality ratio of 0.51x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Silexion Therapeutics Corp cover its interest payments?
Silexion Therapeutics Corp (SLXN) has an interest coverage ratio of -465.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Silexion Therapeutics Corp?
Silexion Therapeutics Corp (SLXN) scores 1 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.